David Barnett, MD
Neurological Surgery · Dallas, TXNPI 1245251743
Payments from drug & device makers
Across 72 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$458
- Argenx US, Inc.$314
- Lilly USA, LLC$229
- Eisai Inc.$108
- Ipsen Biopharmaceuticals, Inc$105
- Merz Pharmaceuticals, LLC$101
- plus $397 from 15 others
What the payments were for
- Food & beverage$1,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 14 | $458 |
| Argenx US, Inc. | 14 | $314 |
| Lilly USA, LLC | 12 | $229 |
| Eisai Inc. | 4 | $108 |
| Ipsen Biopharmaceuticals, Inc | 5 | $105 |
| Merz Pharmaceuticals, LLC | 3 | $101 |
| Lundbeck LLC | 5 | $90 |
| AbbVie | 2 | $42 |
| UCB, Inc. | 1 | $40 |
| SK Life Science, Inc. | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Amgen | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Banner Life Sciences, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,711 in reported general payments places this provider in the 30th percentile of 582 neurological surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 124 | $1,133 |
| Methocarbamol | 55 | $209 |
| Cephalexin | 96 | $209 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $147 |
| Methylprednisolone | 20 | $118 |
| Tramadol Hcl | 21 | $110 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Dallas
- Richard MeyratDallas$883K
- Anthony MaiorielloDallas$328K
- Babu WelchDallas$268K
- Bartley MitchellDallas$255K
- Jeremy DenningDallas$204K
- John DormanOdessa$8.5M
- Daniel PetersonAustin$5.8M
- Daniel CurryHouston$3M
- Peter KanGalveston$1.8M
- Mirza BaigShenandoah$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.